XML 19 R9.htm IDEA: XBRL DOCUMENT v2.4.0.6
Warrants and Derivative Liability
 6 Months Ended
Jun. 30, 2012
Warrants and Derivative Liability
(3) Warrants and Derivative Liability

The Company had 11,292,993 warrants to purchase common shares outstanding at June 30, 2012 at a weighted-average exercise price of $1.44, as summarized in the following table:

 

Issue Date

    Amount        Exercise Price          Expiration Date    

4/27/07

      17,500         17.90         1/17/2014   

12/5/07

      307,967         1.17         12/3/12   

7/31/09

      138,888         1.00         7/30/14   

7/31/09

      1,666,000         1.00         7/30/14   

10/16/09

      8,515,588         1.50         10/15/14   

10/16/09

      647,050         1.50         10/15/14   
  

 

 

     

 

 

     
           11,292,993       $ 1.44      
  

 

 

        
  

 

 

        

October 2009 Warrants

On October 16, 2009, the Company completed a $70.0 million private placement with both existing and new investors resulting in $62.3 million in net proceeds and an additional $3.6 million from bridge notes converted in conjunction with the private placement. In consideration for the $62.3 million in net cash proceeds Amarin issued 66.4 million units, each unit consisting of (i) one ADS (representing one ordinary share) at a purchase price of $1.00 and (ii) a warrant with a five year term to purchase 0.5 of an ADS at an exercise price of $1.50 per ADS. In consideration for the conversion of $3.6 million of convertible bridge notes, Amarin issued 4.0 million units, each unit consisting of (i) one ADS (representing one ordinary share) at a purchase price of $0.90 and (ii) a warrant with a five year term to purchase 0.5 of an ADS at an exercise price of $1.50 per ADS. The total number of warrants issued in conjunction with the financing was 35.2 million.

The warrants issued in connection with the October 2009 financing contain a pricing variability feature which provides for an increase to the exercise price if the exchange rate between the U.S. dollar and British pound adjusts such that the warrants could be issued at a price less than the £0.5 par value of the common stock – that is, if the exchange rate exceeds U.S. $3.00 per £1.0 sterling. Due to the potential variable nature of the exercise price, the warrants are not considered to be indexed to the Company’s common stock. Accordingly, the warrants do not qualify for the exception to classify the warrants within equity and are classified as a derivative liability. The fair value of this warrant derivative liability is remeasured at each reporting period, with changes in fair value recognized in the statement of operations. The fair value of the warrants at December 31, 2011 was determined to be approximately $123.1 million using the Black-Scholes option pricing model.

Although the warrants contain a pricing variability feature, the number of common shares issuable under the warrants remains fixed. Therefore, as of June 30, 2012 the maximum number of common shares issuable as a result of the October 2009 private placement is 9.2 million. During the three and six months ended June 30, 2012, approximately 9.51 million, and 9.55 million of the October 2009 warrants were exercised, respectively, resulting in gross proceeds to the Company of approximately $14.26 million and $14.32 million, respectively. During the three and six months ended June 30, 2011, approximately 5.6 million and 9.6 million of the October 2009 warrants were exercised, respectively, resulting in gross proceeds to the Company of approximately $8.4 million and $14.3 million, respectively. Upon exercise, the fair value of the warrants exercised is remeasured and reclassified from warrant liability to additional paid-in capital. During the six months ended June 30, 2012 and 2011, the fair value of the exercised warrants of $92.3 million and $108.5 million, respectively, was transferred from warrant liability to additional paid in capital with the change in the fair value on the exercise date recognized in the statement of operations. The fair value of the warrant liability at June 30, 2012 for the remaining warrants was determined to be approximately $120.2 million. The Company recognized a loss on change in fair value of derivative liability of $85.2 million and compensation expense of $4.2 million for the six month period ended June 30, 2012. The Company recognized a loss on change in fair value of derivative liability of $160 million and compensation expense of $4.4 million for the six month period ended June 30, 2011.